Title page

Higher long-term visit-to-visit blood pressure variability is associated with severe cerebral small vessel disease in the general population.

Xinyu Zhao^{1#}, Hui Ying^{2#}, Jing Li³, Xianquan Shi⁴, Shuohua Chen⁵, Han Lv², Shouling Wu^{5*}, Zhenchang Wang^{2*}

¹Clinical Epidemiology & EBM Unit, Beijing Friendship Hospital, Capital Medical University; State Key Lab of Digestive Health, National Clinical Research Center for Digestive Diseases, Beijing, China.

² Department of Radiology, Beijing Friendship Hospital, Capital Medical University, Beijing, China

³Department of Radiology, Department of ultrasound, Beijing Friendship Hospital, Capital Medical University, Beijing, China

⁴Department of Cardiology, Kailuan General Hospital, Tangshan, China

⁵Department of Cardiology, Kailuan General Hospital, Tangshan, China

[#] Xinyu Zhao and Hui Ying contributed equally to this work.

*Corresponding author:

Shouling Wu

Department of Cardiology, Kailuan General Hospital, Tangshan 063000, China. E-mail address: drwusl@163.com

Zhenchang Wang

Department of Radiology, Beijing Friendship Hospital, Capital Medical University NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

No.95, Yong An Road, Xicheng District, Beijing 100050, China

E-mail: cjr.wzhch@vip.163.com

Author contribution statement

ZC and SW designed the study, guided the writing of the manuscript, and reviewed the manuscript. XZ analyzed the data. XZ and HY wrote the manuscript. HY, JL, XS, SC, and HL interpreted the data. ZC and SW revised the manuscript. All authors read and approved the final manuscript.

Conflict of interest disclosures

All authors report no conflicts of interest.

Funding

This work was supported by the Beijing Municipal Administration of Hospitals Incubating Program (PX2022001), the National Natural Science Foundation of China (grant numbers: 82272072,61931013), and Beijing Scholars Program (grant number: [2015] 160).

Acknowledgment

The authors thank all the members of the Kailuan Study Team for their contribution and the participants who contributed their data.

Data Availability

Data are available on reasonable request from the corresponding author at cjr.wzhch@vip.163.com.

Abstract

Background:

Long-term blood pressure (BP) variability is related to several diseases, but its impact on cerebral small vessel disease (cSVD) is uncertain. The study explored the relationship between BP variability, total cSVD burden, and its typical features.

Method:

The study involved 1284 participants from the Kailuan cohort. From 2006 to 2022, systolic BP (SBP), diastolic BP (DBP), and pulse pressure (PP) variability were calculated as low, middle, or high. Magnetic resonance imaging was used to identify white matter hyperintensities (WMH), lacunae (LA), cerebral microbleeds (CMBs), and visible perivascular spaces (PVS). The burden of cSVD was defined as non, mild, moderate, or severe. Logistic regression was used to estimate the odds ratio (OR) and confidence interval (CI).

Results:

High SBP variability was associated with moderate cSVD burden (OR=1.89, 95% CI: 1.09-3.29) and PVS (OR= 1.62, 95%CI: 1.10-2.39). The DBP was associated with LA (OR=1.74, 95%CI: 1.06-2.84). The PP showed obvious risk effects on moderate/severe cSVD burden (OR= 1.99, 95%CI: 1.17-3.41; OR=2.49, 1.34-4.63). These associations were modified by age and hypertension status. In the young adults (age<60 years old), only high PP variability associated with severe cSVD burden (OR=3.33, 95%CI: 1.31-8.44), LA (OR=3.02, 95%CI: 1.31-6.93), and PVS (OR=1.86, 95%CI: 1.20-2.88). The risk effect of SBP and PP variability on cSVD burden was only significant in the participants with hypertension.

Conclusion:

High long-term BP variability, especially in combination with hypertension, is a risk factor for total cSVD burden, LA, and PVS. it is crucial to pay attention to PP variability in young adults.

Keyword:

Blood pressure variability, cerebral small vessel disease, white matter hyperintensities, lacunae, cerebral microbleeds, visible perivascular spaces.

Abbreviations: Cerebral small vessel disease (cSVD), white matter hyperintensities (WMHs), lacunae of presumed vascular origin (LA), cerebral microbleeds (CMBs), visible perivascular spaces (PVS), magnetic resonance (MR), blood pressure (BP), systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse pressure (PP), and multi-modality medical imaging study (META-KLS)

1 Introduction

Cerebral small vessel disease (cSVD) is a chronic progressive disorder that refers to a group of conditions affecting the small blood vessels in the brain ¹. Typical identified cSVD subtypes include white matter hyperintensities (WMH), lacunae of presumed vascular origin (LA), cerebral microbleeds (CMBs), and visible perivascular spaces (PVS)². Patients with cSVD are at an increased risk of stroke, transient ischemic attack depression, and vascular dementia, finally causing disability and mortality³. The disease's mechanism remains unclear, leading to no practical preventative or therapeutic approach for cSVD⁴. Total cSVD burden, which sums up the different magnetic resonance imaging (MRI) features that were present, was a simple and effective indicator that captured the overall effect of SVD on the brain. It is meaningful to explore factors that increase the risk of incidence of cSVD or the severity of cSVD burden, finding potential measures for disease prevention.

The concept of visit-to-visit blood pressure (BP) variability is not new⁵. Numeric evidence has suggested that BP variability is a significant independent risk factor for several diseases, especially cardiovascular events, regardless of average BP⁶⁻⁸. Though a meta-analysis showed that BP variability was associated with cSVD, the positive relationship was only significant using 24-hour ambulatory BP monitoring and short-term (<6 months) visit-to-visit BPV⁹. The evidence on the relationship between long-term visit-to-visit BP and cSVD is still limited. Furthermore, most existing studies assessed WMH, while evidence on the total cSVD burden and other cSVD subtypes, including LA, CMBs, and PVS, is sparse.

So, based on the Kailuan cohort study, the present study aimed to explore the relationship between long-term visit-to-visit BPV and total cSVD burden and every typical cSVD feature.

2 Method

2.1 Study population

This is a cross sectional study based on an ongoing longitudinal prospective cohort study, the Kailuan study, as detailed elsewhere ^{10,11}. From 2006 to 2007, 101 510 participants in the Kailuan community were enrolled, and follow-up surveys were conducted biennially. The study has

finished eight surveys (2006-2007, 2008-2009, 2010-2011, 2012-2013, 2014-2015, 2016-2017, 2018-2019, and 2020-2022). At the recent survey (2020-2022), we additionally performed a multi-modality medical imaging study (META-KLS), which enrolled subjects who participated in the Kailuan study and were asked to complete multi-modality medical imaging, including brain MR imagingscan, retinal fundus photograph, and so on. The detailed rationale and design of META-KLS has been published online¹². The study enrolled 1508 participants who agreed on the META-KLS and completed brain MR imaging. We excluded 224 participants due to the following: (1) having less than three visits of BP measure during the past eight surveys (N=174); (2) having a stroke at present examination (N=3); (3) having cancer at present examination (N=1); and (4) more than half of the covariate information is missing (N=46). Finally, 1284 participants were included in the analysis (Figure 1.).

2.2 Ethics Statement

The Medical Ethics Committee of Kailuan General Hospital has approved both the Kailuan Study and META-KLS (IRB Number: 2008 No.1 and 2021002, respectively). These two cohort studies were registered online (ChiCTR2000029767 on chictr.org.cn and NCT05453877 on Clinicaltrials.gov, respectively). Informed consent was obtained from all participants included in the study.

2.3 Variability of BP assessment

The BP, including systolic BP (SBP) and diastolic BP (DBP), was measured in the left upper arm using a calibrated mercury sphygmomanometer while the participant sat. At least 2 BP measurements were taken after 5 min of rest. BP was then measured again if the difference between the two measurements was more than 5 mm Hg. The final BP value was recorded as the average value of the BP measurements, and pulse pressure (PP) was calculated as SBP minus DBP. Hypertension was defined as systolic blood pressure \geq 140 mm Hg and diastolic blood pressure \geq 90 mm Hg, currently receiving antihypertensive treatment, or having a self-reported physician diagnosis.

Four indices of variability were used: (1) coefficient of variation (CV), (2) standard deviation (SD), and (3) variability independent of the mean (VIM); VIM was calculated as SD/mean. It is similar to CV except that the mean BP denominator is raised to a specific power, x, that removes any correlation with mean BP. Power x is modeled as $SD = k \times$ means and was derived from fitting curves by nonlinear regression analysis as implemented in the PROC NLIN procedure of the SAS package⁵. (4) average natural variability (ARV) is the average absolute difference between successive values¹³. The VIM was used as the primary variability measure.

2.4 MR imaging and definition of cSVD

The brain MR imaging was collected using a 3.0 Tesla scanner and an eight-channel phased-array coil (GE 750W; General Electric Medical Systems, Milwaukee, WI, USA). The sequences used in the MRI examination included the following: axial T2-weighted imaging, three-dimensional (3D) brain volume (BRAVO) for high-resolution T1-weighted imaging, 3D fluid-attenuated inversion recovery imaging, diffusion-weighted imaging (DWI), and susceptibility-weighted angiography (SWAN).

According to the Standards for Reporting Vascular Changes on Neuroimaging 2 (STRIVE-2), ²,4 closely correlated features are markers of cSVD were assessed, including (1) LA, which was defined as the presence of one or more lacunes (1 point if present); (2) CMBs, which was defined as the presence of one or more CMB (1 point if present); (3). PVS, which was defined as there were moderate to severe (grade 2–4) PVS in the basal ganglia (1 point if present); (4) WMH, which was defined as either (early) confluent deep WMH (Fazekas score 2 or 3) or irregular periventricular WMH extending into the deep white matter (Fazekas score 3) (1 point if present). The total burden of cSVD was rated on an ordinal scale from 0 to 4 by counting the presence of each of the 4 MRI features of cSVD. And then defined as a categorical variable, including non-cSVD if the total burden is zero, mild cSVD if the entire burden is one, moderate cSVD if the total burden is 2, and severe cSVD if the total burden is 3 or 4.

All images, including WMH, Lacunes, CMBs, and PVS, were independently evaluated by two experienced neuroradiologists. The consistency of vision has been proved in our previous study¹⁴.

2.5 Potential confounders

We conducted questionnaire surveys to collect the following information, including age (18-59 years old, or \geq 60 years old), gender, education level (junior high school or below, senior high school, or college and above), smoking status (never smoking, past smoking, or current smoking), drinking status (never drinking, past drinking, or everyday drinking), physical activity, disease history, and medications. We categorized the physical activity level as "inactive," "moderately active," or "active" according to the frequency of physical activity (>20 min/time) during leisure time; if the response was "never," "sometimes," or " \geq four times/week," correspondingly. Trained field workers measured height and weight, and body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared. Laboratory tests, including fasting blood glucose, triglycerides (TG), high-density lipoprotein cholesterol (HDL-c), and low-density lipoprotein cholesterol (LDL-c) were assessed in the central lab. Diabetes was defined as fasting blood glucose \geq 7.0 mmol/L, taking oral hypoglycaemic agents or insulin, or having a self-reported physician diagnosis.

2.6 Statistical methods

Variables were presented as mean \pm standard deviation or number (%) and compared using analysis of variance or Chi-square test, respectively.

For the test of parallel lines was not fitted, multinomial logistic regressions were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) of the BP variability on the total burden of cSVD (mild *vs.* non, moderate *vs.* non, and severely non). Unconditional logistic regressions assessed the association between BP variability and the four markers of cSVD (WMH, LA, CMBs, and PVS). BP variability was categorized into three groups (< p25 as low, p25-p75 as middle, or \geq p75 as high). Three multivariate models were constructed to control for possible confounding effects: (1) age- and gender-adjusted model, which adjusted baseline age (2020-2022 survey) and gender; (2) multivariate model 1, which further adjusted education level, drinking status, smoking status, physical activity level, baseline BMI, diabetes, TG, HDL, and LDL level. (3) Multivariate

model 2 is based on multivariate model 1 and further adjusted the mean value of SBP, DBP, or PP when the exposure was the corresponding variability of the BP indicator.

Assuming that missing data was random, we used multiple imputations by chained equations to impute one complete dataset with five interactions, which showed equal distribution before and after imputation (Supplementary Table 1). Subgroup analyses were performed according to age group, gender, and hypertension status to test the potential modification effect. We also conducted sensitivity analyses to verify the results: (1) using the original complete dataset, (2) excluding participants with diabetes, (3) excluding participants who are currently taking antihypertensive medications.

The main results were shown using the multivariate model 2. For the detailed results, see the supplementary tables 3-10. Analyses were implemented with SAS version 9.4 (SAS Institute Inc. Cary, NC) or R version 3.5.2 (https://www.r-project.org/).

3 Results

3.1 Baseline characteristics and the prevalence of cSVD burden

Of the invited 1284 participants, the mean age was 56.5±11.8 years old, and 52.7% were male. The mean follow-up duration was 13.1±3.0 years. cSVD was identified in 890 (69.3%) participants at the baseline, including 212 (16.5%) LA, 351 (27.3%) CMBs, 785 (61.1%) PVS, and 346 (27.0%) WMH. For the patients with cSVD, 415(46.6%) had mild cSVD burden, 252(28.3%) had moderate cSVD burden, and 223(25.1%) had severe cSVD burden (supplementary table S2). Compared with the participants without a cSVD burden, the subjects with a cSVD burden were significantly older, were more male, had lower education but higher physical activity levels, were generally smokers and drinkers, were usually diabetes, hypertension, had slightly higher BMI and LDL-c level, while had lower HDL-c level. There was no significant difference between the participants with and without cSVD in follow-up durations. (table 1)

3.2 Associations between BP variability and burden of cSVD/different markers of cSVD

Figure 2 shows the associations between BP variability and the burden of cSVD. Compared with low variability of SBP, higher SBP variability was significantly associated with moderate cSVD burden (middle *vs* low: OR=1.66, 95%CI: 1.03-2.65, p = 0.036; high *vs* low: OR=1.89, 95%CI: 1.09-3.29, p = 0.023). High SBP variability showed a risk effect on the severe cSVD burden on the boundary of significance (OR=1.75, 95%CI: 1.09-3.29, p = 0.067). For the markers of cSVD, High SBP variability was significantly associated with PVS (OR= 1.62, 95%CI: 1.10-2.39, p =0.015). High DBP variability was only observed to be associated with LA (OR=1.74, 95%CI: 1.06-2.84, p = 0.082). High PP variability showed more obvious risk effects on moderate/severe cSVD burden (moderate cSVD burden: OR= 1.99, 95%CI: 1.17-3.41, p = 0.012, severe cSVD burden: OR=2.49, 1.34-4.63, p = 0.004), LA (OR=1.75, 95%CI:1.06-2.89, p = 0.028), and PVS (OR=1.77, 95%CI: 1.20-2.61, p = 0.004).

3.3 Associations between BP variability and burden of cSVD/different markers of cSVD by age groups

Figure 3 shows the estimated risk of BP variability on cSVD burden and different markers of cSVD by age group. For participants under 60 years old, high variability of SBP was significantly associated with PVS(OR=1.65,95%CI: 1.06-2.58, p = 0.027), High variability of PP was significantly associated with moderate (OR=2.04,95%CI: 1.03-4.06, p = 0.042), severe cSVD burden (OR=3.33,95%CI: 1.31-8.44, p = 0.011), LA (OR=3.02,95%CI: 1.31-6.93, p = 0.009), and PVS(OR=1.86,95%CI: 1.20-2.88, p = 0.006). The variability of DBP was not observed to be associated with LA for participants 60 years or older (OR=2.37,95%CI: 1.26-4.45, p = 0.007). Only high variability of SBP showed a significant risk effect on the moderate cSVD burden (OR=4.87, 95%CI:1.14-20.83, p = 0.033) and severe cSVD burden on the boundary of significance (OR=3.87, 95%CI: 0.90-16.74, p = 0.070).

3.4 Associations between BP variability and burden of cSVD/different markers of cSVD by gender and hypertension status.

The association between BP variability and cSVD burden or different markers of cSVD were consistent both in males and females (Figure 4). Stratified by hypertension status, the risk effect of

higher variability of SBP (middle vs low variability for moderate cSVD burden: OR=2.10, 95%CI:1.05-4.18, p = 0.035) and PP (high vs low variability for severe cSVD burden: OR=2.32, 95%CI:1.03-5.22, p = 0.042) on cSVD burden were only significantly positive in the participants with hypertension. (Figure 5).

3.5 Sensitivity analyses

Using original data, excluding the participants with diabetes, excluding participants who are currently taking antihypertensive medications, or using other variability indicators, the estimated impact of BP variability on cSVD burden and different markers did not change substantially (table 2, supplementary table 11-12).

4 Discussion

In this study, we identified cSVD in 890 (69.3%) participants in this sub-study of a population-based cohort. We showed that higher long-term visit-to-visit BPV was an independent risk factor for cSVD, including the total cSVD burden, LA, and PVS. Notably, we found that the risk effect of BPV on cSVD differs by age.

Our study showed that higher visit-to-visit variability in SBP, not DBP, was significant with total cSVD burden. Recently, two meta-analysis studies have demonstrated that BPV was independently associated with CSVD^{9,15}. However, these studies primarily defined the cSVD as WMH. Until now, little study has explored the relationship between long-term visit-to-visit BPV and total cSVD burden. Two other studies showed that short-term (twenty-four-hour)¹⁶ or middle-term (day-to-day)¹⁷ SBP variability was associated with total cSVD burden but did not observe a significant association between DBP variability and total cSVD burden, which was consistent with our study to a certain extent. The underlying mechanisms between BPV and cSVD are still poorly understood. There are several possible explanations. Firstly, high BPV may increase blood flow pulsation and dampen blood flow smoothing, causing damage to brain microvasculature¹⁸. Secondly, high BPV can potentially hinder nitric oxide production and compromise endothelial function. This could lead to injuries in the "neurovascular unit," abnormalities in the blood-brain barrier, and, consequently, lesions in small blood vessels¹⁹⁻²¹. It has been proposed that increased variability in blood pressure may stem from pre-existing brain diseases disrupting central autonomic control²². Calcium channel blockers, recognized as the most effective drug class for mitigating variability in blood pressure, have demonstrated noteworthy

efficacy in reducing the risk of vascular cognitive impairment^{23,24}. This observation underscores the potential clinical significance of agents targeting blood pressure variability in diminishing the risk of brain vascular disease and cognitive impairment in old age.

For the specific markers of cSVD, we found that the risk effect of long-term variability on SBP was mainly on the PVS (high *vs* low: OR= 1.62, 95% CI: 1.10-2.39, p = 0.015), and DBP variability only had a risk effect on LA (high *vs*. low: OR=1.74, 95% CI: 1.06-2.84, p = 0.082. Studies have shown that the high level of office SBP, 24-hour ambulatory SBP²⁵, and cumulative SBP were the risk factors for PVS²⁶. Our study showed that the long-term variability of SBP was also an independent risk factor for PVS. The relationship between DBP and LA has not been thoroughly studied yet. Furthermore, our study showed that long-term variability of PP seemed to have a more significant risk effect on total cSVD burden, LA, and PVS than SBP and DBP. Previous studies evaluated BPV most frequently using SBP or DBP, few studies employed PP. So far, studies have reported that PP was a better predictor of cardiovascular²⁷ and cerebrovascular²⁸ risk than diastolic or systolic pressure. Studies showed PP was associated with the cognitive independence of SBP^{29,30}. Increased PP and its variability might represent diminished regulatory functions of vessels against pulsate blood flow, making the brain tissues more susceptible to direct injury.

We did not observe a significant association between BPV and other markers of cSVD, including WMH and CMBs. However, most existing studies showed that BPV was a risk factor for WMH. These studies mostly used the SD CV as the BPV indicator but did not consider the potential confounding effect of the mean value of BP³¹⁻³⁴. It is difficult to determine whether BPV has an independent risk effect on cSVD besides the absolute BP level. Our data also showed that high SBP variability of SD was significantly associated with WMH (OR=1.73, 95%CI:1.15-2.62, p=0.009). However, this association disappeared when the mean level of SBP was adjusted, which was consistent with a previous study. It demonstrated that the BPV is closely related to the absolute level of BP and may act on some common pathways for WMH³⁵. The relationship between BPV and CMBs remains limited and conflicting ^{15,35-37}, which need more research to identify their relationship.

An interesting finding in our present study is that the risk effect of BPV on cSVD differs by age. High variability of PP significantly affected total cSVD burden, LA, and PVS only for patients aged < 60 years old. Higher PP is related to cerebral microvascular damage; an animal experiment recently showed that its risk effect is age-dependent³⁸. The greater stiffness of cerebral arteries from old potentially protects against the negative consequences of high PP variability. It suggested that more attention for PP besides SBP and DBP for young adults is needed to reduce the risk of cSVD. For patients aged \geq 60 years old, the risk effect of high SBP variability on total cSVD

burden and high DBP variability on LA appeared. It showed that SBP variability has an overall risk effect on cerebral small vessel disease, rather than by considering only one individual feature separately. Additionally, our data suggested that the risk effect of BP variability may modified by hypertension status. The risk effect of high BP variability was more evident in the participants with hypertension. It may be due to the hypertension group was more likely to have high fluctuation in blood pressure, for poor medication compliance. So, BP management, including both the high absolute level and variability of BP, is crucial for hypertension patients to prevent cSVD.

For the strengths, previous studies mainly focused on some specific features of cSVD, especially for WMH, while evidence on LA and PVS is sparse. The present study explored the relationship between BPV and four features of cSVD, including LA, WMH, CMBs, and PVS, in a relatively large sample. Furthermore, we verified the overall risk effects of BPV on the total cSVD burden, which takes all features of cSVD. Novelly, we found that the risk effect of BPV on cSVD differs by age. For young adults (age<60), steady fluctuation of PP was also an important intervention target, which needs more research to confirm. From a methodological standpoint, we employ VIM as the primary measure of variability. VIM was explicitly developed as a new measure of variability uncorrelated with mean blood pressure⁵. In our multivariate model, we adjust the mean blood pressure level, indicating that BPV impacts cSVD independently of mean blood pressure. Several limitations of our study should be noted. Firstly, MRI examinations were only performed once in the current survey, so potential reverse causation remains a major issue. This study is a nested case-control study derived from a 13-year follow-up cohort, ensuring the measurement accuracy for exposure, confounders, and outcome. Additionally, our study is still in progress, and the population with no cSVD will still be followed up. The relationship between BPV and the occurrence of cSVD will be retested in future studies. Secondly, the participants receiving the MRI were a small proportion of the original cohort; there were still likely potential selection biases beyond the confounders included in the study.

Conclusions

Higher long-term visit-to-visit BP variability was an independent risk factor for cSVD, including the total cSVD burden, LA, and PVS, especially for the participants with hypertension. For young adults (age<60 years old), higher PP variability may be a more critical risk factor for cSVD than SBP and DBP.

References

1. Chojdak-Łukasiewicz J, Dziadkowiak E, Zimny A, Paradowski B. Cerebral small vessel disease: A review. Adv Clin Exp Med. 2021;30:349-356. doi: 10.17219/acem/131216

2. Staals J, Makin SD, Doubal FN, Dennis MS, Wardlaw JM. Stroke subtype, vascular risk factors, and total MRI brain small-vessel disease burden. Neurology. 2014;83:1228-1234. doi: 10.1212/wnl.00000000000837

3. Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and clinical implications. Lancet Neurol. 2019;18:684-696. doi: 10.1016/s1474-4422(19)30079-1

4. Gao Y, Li D, Lin J, Thomas AM, Miao J, Chen D, Li S, Chu C. Cerebral small vessel disease: Pathological mechanisms and potential therapeutic targets. Front Aging Neurosci. 2022;14:961661. doi: 10.3389/fnagi.2022.961661

5. Dolan E, O'Brien E. Blood pressure variability: clarity for clinical practice. Hypertension. 2010;56:179-181. doi: 10.1161/hypertensionaha.110.154708

 Kim MK, Han K, Park YM, Kwon HS, Kang G, Yoon KH, Lee SH. Associations of Variability in Blood Pressure, Glucose and Cholesterol Concentrations, and Body Mass Index With Mortality and Cardiovascular Outcomes in the General Population. Circulation. 2018;138:2627-2637. doi: 10.1161/circulationaha.118.034978

7. Yuan Y, Liu M, Zhang S, Lin Y, Huang Y, Zhou H, Xu X, Zhuang X, Liao X. Effect of blood pressure index on clinical outcomes in patients with heart failure and chronic kidney disease. ESC Heart Fail. 2023. doi: 10.1002/ehf2.14437

8. Wu S, Tian X, Xu Q, Zhang Y, Zhang X, Wang P, Chen S, Wang A. Visit-to-visit blood pressure variability and the risk of cardiovascular disease: a prospective cohort analysis. Hypertens Res. 2023. doi: 10.1038/s41440-023-01388-7

 Tully PJ, Yano Y, Launer LJ, Kario K, Nagai M, Mooijaart SP, Claassen J, Lattanzi S, Vincent AD, Tzourio C. Association Between Blood Pressure Variability and Cerebral Small-Vessel Disease: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2020;9:e013841. doi: 10.1161/jaha.119.013841

10. Wu S, Huang Z, Yang X, Zhou Y, Wang A, Chen L, Zhao H, Ruan C, Wu Y, Xin A, et al. Prevalence of ideal cardiovascular health and its relationship with the 4-year cardiovascular events in a northern Chinese industrial city. Circ Cardiovasc Qual Outcomes. 2012;5:487-493. doi: 10.1161/CIRCOUTCOMES.111.963694

 Wang A, Wu J, Zhou Y, Guo X, Luo Y, Wu S, Zhao X. Measures of adiposity and risk of stroke in China: a result from the Kailuan study. PLoS One. 2013;8:e61665. doi: 10.1371/journal.pone.0061665

 Sun J, Hui Y, Li J, Zhao X, Chen Q, Li X, Wu N, Xu M, Liu W, Li R, et al. Protocol for Multi-modality MEdical imaging sTudy bAsed on KaiLuan Study (META-KLS): rationale, design and database building. BMJ Open. 2023;13:e067283. doi: 10.1136/bmjopen-2022-067283
Mena L, Pintos S, Queipo NV, Aizpúrua JA, Maestre G, Sulbarán T. A reliable index for the prognostic significance of blood pressure variability. J Hypertens. 2005;23:505-511. doi: 10.1097/01.hjh.0000160205.81652.5a

14. Shi H, Cui L, Hui Y, Wu S, Li X, Shu R, Song H, Wang J, Yu P, Chen S, et al. Enlarged Perivascular Spaces in Relation to Cumulative Blood Pressure Exposure and Cognitive Impairment. Hypertension. 2023. doi: 10.1161/hypertensionaha.123.21453

15. Ma Y, Song A, Viswanathan A, Blacker D, Vernooij MW, Hofman A, Papatheodorou S. Blood Pressure Variability and Cerebral Small Vessel Disease: A Systematic Review and Meta-Analysis of Population-Based Cohorts. Stroke. 2020;51:82-89. doi:

10.1161/strokeaha.119.026739

16. Yang S, Yuan J, Qin W, Yang L, Fan H, Li Y, Hu W. Twenty-four-hour ambulatory blood pressure variability is associated with total magnetic resonance imaging burden of cerebral small-vessel disease. Clin Interv Aging. 2018;13:1419-1427. doi: 10.2147/cia.S171261 17. de Heus RAA, Reumers SFI, van der Have A, Tumelaire M, Tully PJ, Claassen J.

Day-to-Day Home Blood Pressure Variability is Associated with Cerebral Small Vessel Disease Burden in a Memory Clinic Population. J Alzheimers Dis. 2020;74:463-472. doi: 10.3233/jad-191134

18. Mitchell GF, van Buchem MA, Sigurdsson S, Gotal JD, Jonsdottir MK, Kjartansson Ó, Garcia M, Aspelund T, Harris TB, Gudnason V, et al. Arterial stiffness, pressure and flow pulsatility and brain structure and function: the Age, Gene/Environment Susceptibility--Reykjavik study. Brain. 2011;134:3398-3407. doi: 10.1093/brain/awr253

19. Abbott NJ, Rönnbäck L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006;7:41-53. doi: 10.1038/nrn1824

20. Eto M, Toba K, Akishita M, Kozaki K, Watanabe T, Kim S, Hashimoto M, Sudoh N, Yoshizumi M, Ouchi Y. Reduced endothelial vasomotor function and enhanced neointimal formation after vascular injury in a rat model of blood pressure lability. Hypertens Res. 2003;26:991-998. doi: 10.1291/hypres.26.991

21. Wardlaw JM. Blood-brain barrier and cerebral small vessel disease. J Neurol Sci. 2010;299:66-71. doi: 10.1016/j.jns.2010.08.042

22. Kario K, Motai K, Mitsuhashi T, Suzuki T, Nakagawa Y, Ikeda U, Matsuo T, Nakayama T, Shimada K. Autonomic nervous system dysfunction in elderly hypertensive patients with abnormal diurnal blood pressure variation: relation to silent cerebrovascular disease. Hypertension. 1997;30:1504-1510. doi: 10.1161/01.hyp.30.6.1504

23. Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet. 2010;375:906-915. doi: 10.1016/s0140-6736(10)60235-8

24. Alagiakrishnan K, McCracken P, Feldman H. Treating vascular risk factors and maintaining vascular health: is this the way towards successful cognitive ageing and preventing cognitive decline? Postgrad Med J. 2006;82:101-105. doi: 10.1136/pgmj.2005.035030

25. Yang S, Yuan J, Zhang X, Fan H, Li Y, Yin J, Hu W. Higher ambulatory systolic blood pressure independently associated with enlarged perivascular spaces in basal ganglia. Neurol Res. 2017;39:787-794. doi: 10.1080/01616412.2017.1324552

26. Shi H, Cui L, Hui Y, Wu S, Li X, Shu R, Song H, Wang J, Yu P, Chen S, et al. Enlarged Perivascular Spaces in Relation to Cumulative Blood Pressure Exposure and Cognitive Impairment. Hypertension. 2023;80:2088-2098. doi: 10.1161/hypertensionaha.123.21453

27. García-Ortiz L, Gómez-Marcos MA, Martín-Moreiras J, González-Elena LJ,

Recio-Rodriguez JI, Castaño-Sánchez Y, Grandes G, Martínez-Salgado C. Pulse pressure and nocturnal fall in blood pressure are predictors of vascular, cardiac and renal target organ damage in hypertensive patients (LOD-RISK study). Blood Press Monit. 2009;14:145-151. doi: 10.1097/MBP.0b013e32832e062f

28. Kamieniarz-Mędrygał M, Kaźmierski R. Significance of pulse pressure variability in predicting functional outcome in acute ischemic stroke: a retrospective, single-center, observational cohort study. Sci Rep. 2023;13:3618. doi: 10.1038/s41598-023-30648-2 29. Mizuhara R, Mitaki S, Takamura M, Abe S, Onoda K, Yamaguchi S, Nagai A. Pulse pressure

is associated with cognitive performance in Japanese non-demented population: a cross-sectional study. BMC Neurol. 2022;22:137. doi: 10.1186/s12883-022-02666-6

30. Sha T, Cheng W, Yan Y. Prospective associations between pulse pressure and cognitive performance in Chinese middle-aged and older population across a 5-year study period. Alzheimers Res Ther. 2018;10:29. doi: 10.1186/s13195-018-0355-1

31. Havlik RJ, Foley DJ, Sayer B, Masaki K, White L, Launer LJ. Variability in midlife systolic blood pressure is related to late-life brain white matter lesions: the Honolulu-Asia Aging study. Stroke. 2002;33:26-30. doi: 10.1161/hs0102.101890

32. Leung LY, Bartz TM, Rice K, Floyd J, Psaty B, Gutierrez J, Longstreth WT, Jr., Mukamal KJ. Blood Pressure and Heart Rate Measures Associated With Increased Risk of Covert Brain Infarction and Worsening Leukoaraiosis in Older Adults. Arterioscler Thromb Vasc Biol. 2017;37:1579-1586. doi: 10.1161/atvbaha.117.309298

33. Tsukishima E, Saito H, Shido K, Kobashi G, Ying-Yan G, Kishi R, Niino M, Kondo K, Sugimura I. Long-term blood pressure variability and cerebrovascular changes on CT in a community-based elderly population. J Epidemiol. 2001;11:190-198. doi: 10.2188/jea.11.190

34. Brickman AM, Reitz C, Luchsinger JA, Manly JJ, Schupf N, Muraskin J, DeCarli C, Brown TR, Mayeux R. Long-term blood pressure fluctuation and cerebrovascular disease in an elderly cohort. Arch Neurol. 2010;67:564-569. doi: 10.1001/archneurol.2010.70

35. Sabayan B, Wijsman LW, Foster-Dingley JC, Stott DJ, Ford I, Buckley BM, Sattar N, Jukema JW, van Osch MJ, van der Grond J, et al. Association of visit-to-visit variability in blood pressure with cognitive function in old age: prospective cohort study. Bmj. 2013;347:f4600. doi: 10.1136/bmj.f4600

36. Ma Y, Yilmaz P, Bos D, Blacker D, Viswanathan A, Ikram MA, Hofman A, Vernooij MW, Ikram MK. Blood Pressure Variation and Subclinical Brain Disease. J Am Coll Cardiol. 2020;75:2387-2399. doi: 10.1016/j.jacc.2020.03.043

37. Bao Y, Gu J, Lv T, Chen M, Zhao K, Yang Y, Gu D. Correlation between blood pressure variability and deep cerebral microbleeds in patients with acute ischemic stroke. Folia Neuropathol. 2023;61:309-316. doi: 10.5114/fn.2023.130006

38. Winder NR, Reeve EH, Kronquist EK, Khurana A, Lee B, Nguyen T, Henson GD, Walker AE. High pulse pressure impairs cerebral artery endothelial function in young, but not old, mice. Exp Gerontol. 2023;173:112101. doi: 10.1016/j.exger.2023.112101

Figure legends

Figure 1. The flow chart of the study participants

Abbreviations: Cerebral small vessel disease (cSVD) white matter hyperintensities (WMHs), lacunae of presumed vascular origin (LA), cerebral microbleeds (CMBs), visible perivascular

spaces (PVS), magnetic resonance (MR), and blood pressure (BP).

Figure 2. The associations between BP variability, total cSVD burden, and typical features of cSVD.

Abbreviations: Cerebral small vessel disease (cSVD) white matter hyperintensities (WMHs), lacunae of presumed vascular origin (LA), cerebral microbleeds (CMBs), and visible perivascular spaces (PVS), systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse pressure (PP).

Adjusted OR: Adjusted for baseline age (2020-2022 survey), gender, education level, drinking status, smoking status, physical activity level, baseline BMI, diabetes, TG, HDL, LDL level and the mean value of SBP, DBP, or PP when the exposure was the corresponding variability of the BP indicator.

Figure 3. The associations between BP variability, total cSVD burden, and typical features of cSVD by age groups.

Abbreviations: Cerebral small vessel disease (cSVD) white matter hyperintensities (WMHs), lacunae of presumed vascular origin (LA), cerebral microbleeds (CMBs), and visible perivascular spaces (PVS), systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse pressure (PP).

Adjusted OR: Adjusted for gender, education level, drinking status, smoking status, physical activity level, baseline BMI, diabetes, TG, HDL, LDL level and the mean value of SBP, DBP, or PP when the exposure was the corresponding variability of the BP indicator.

Figure 4. The associations between BP variability, total cSVD burden, and typical features of cSVD by gender.

Abbreviations: Cerebral small vessel disease (cSVD) white matter hyperintensities (WMHs), lacunae of presumed vascular origin (LA), cerebral microbleeds (CMBs), and visible perivascular spaces (PVS), systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse pressure (PP).

Adjusted OR: Adjusted for baseline age (2020-2022 survey), education level, drinking status, smoking status, physical activity level, baseline BMI, diabetes, TG, HDL, LDL level and the mean value of SBP, DBP, or PP when the exposure was the corresponding variability of the BP indicator.

Figure 5. The associations between BP variability, total cSVD burden, and typical features of cSVD by hypertension status.

Abbreviations: Cerebral small vessel disease (cSVD) white matter hyperintensities (WMHs), lacunae of presumed vascular origin (LA), cerebral microbleeds (CMBs), and visible perivascular spaces (PVS), systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse pressure (PP).

Adjusted OR: Adjusted for baseline age (2020-2022 survey), education level, drinking status, smoking status, physical activity level, baseline BMI, diabetes, TG, HDL, LDL level and the mean value of SBP, DBP, or PP when the exposure was the corresponding variability of the BP indicator.

	All	non-cSVD	mild cSVD	moderate cSVD	severe cSVD	
Variables	(N=12 84)	(N=394)	(N=415)	(N=252)	(N=223)	<i>p</i> value
Age (n, %)						
18-59 years old	795(6 1.9)	368(93.4)	280(67.5)	98(38.9)	49(22.0)	<0.001
≥60 years old	489(3 8.1)	26(6.6)	135(32.5)	154(61.1)	174(78.0)	
Male (n, %)	678(5 2.8)	156(39.6)	198(47.7)	154(61.1)	170(76.2)	<0.001
Follow-up duration,	13.1±					
years (mean±SD)	3.0	13.0±2.8	13.1±3.1	13.0±3.2	13.3±2.8	0.691
Education level (%)						<0.001
Junior high school or below	521(4 0.6)	88(22.3)	153(36.9)	138(54.8)	142(63.7)	
Senior high school	258(2 0.1)	81(20.6)	90(21.7)	49(19.4)	38(17.0)	
College and above	505(3 9.3)	225(57.1)	172(41.4)	65(25.8)	43(19.3)	
Physical activity level (n, %)						
Inactive	173(1 3.5)	68(17.3)	54(13.0)	26(10.3)	25(11.2)	<0.001
Moderate	972(7 5.7)	302(76.6)	319(76.9)	187(74.2)	164(73.5)	
Frequently	139(1 0.8)	24(6.1)	42(10.1)	39(15.5)	34(15.3)	
Smoking status (n, %)						
Never	921(7 1.7)	316(80.2)	311(75.0)	167(66.3)	127(56.9)	<0.001
Past	51(4.0)	11(2.8)	12(2.9)	16(6.3)	12(5.4)	
Current	312(2 4.3)	67(17.0)	92(22.1)	69(27.4)	84(37.7)	
Drinking status (n, %)						
Never	727(5 6.6)	237(60.1)	248(59.8)	142(56.3)	100(44.8)	<0.001
Past	20(1.6)	3(0.8)	3(0.7)	4(1.6)	10(4.5)	
Current	537(4 1.8)	154(39.1)	164(39.5)	106(42.1)	113(50.7)	

Table1. Baseline characteristics of subjects with different levels of cSVD

medRxiv preprint doi: https://doi.org/10.1101/2024.01.02.24300738; this version posted January 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in													
	perpetuity. All rights reserved. No reuse allowed without permission.												
$Dicketee (n, \theta)$	199(1					<0.001							
Diabetes (n, %)	5.5)	33(8.4)	47(11.3)	58(23.0)	61(27.4)	<0.001							
$ _{y=0}$	724(5					-0.001							
Hypertension (n, %)	6.4)	138(35.0)	219(52.8)	179(71.0)	188(84.3)	<0.001							
$DM = \{r_{n}, r_{n}\}$	25.3±					0.049							
BMI, kg/m² (mean±SD)	3.5	25.1±3.7	25.2±3.5	25.7±3.2	25.7±3.4	0.048							
TC mmol/L [modion(n25 n75)]	1.3(2.					0.875							
TG, mmol/L [median(p25,p75)]	6,3.7)	1.3(0.9,2.0)	1.4(1.0,2.0)	1.4(1.0,2.1)	1.4(1.0,2.0)	0.675							
	1.5±0.					-0.001							
HDL-c, mmol/L (mean±SD)	4	1.5±0.4	1.5±0.4	1.4±0.3	1.4±0.4	<0.001							
DL a mmal// (maan (CD)	3.2±0.					0.001							
LDL-c, mmol/L (mean±SD)	8	3.1±0.8	3.3±0.8	3.2±0.8	3.1±0.9	0.001							

Abbreviations: cSVD: cerebral small vessel disease; non-cSVD: if the total burden is zero; mild cSVD: if the total burden is one; moderate cSVD: if the total burden is 2; and severe cSVD: if the total burden is 3 or 4; BMI: b ody mass index; TG: triglycerides; HDL-c: high-density lipoprotein cholesterol; LDL-c: low-density lipoprotein c holesterol.

	group	n/N	unadjusted O R(95%Cl)	<i>p</i> valu e	age- and gen der- adjusted OR (95%CI)	<i>p</i> valu e	multi adjusted OR₁(95%CI)	<i>p</i> val ue	multi adjusted OR ₂ (95%CI)	<i>p</i> valu e
	VIM of SBP									
	non vs mild cSVD burden									
	low	101/21 7	reference	-	reference	-	reference	-	reference	-
	middle	214/40 3	1.30(0.93-1.8 1)	0.120	1.32(0.93-1.8 6)	0.120	1.13(0.77-1.6 4)	0.53 5	1.17(0.79-1.7 1)	0.433
	high	100/18 9	1.29(0.87-1.9 1)	0.201	1.40(0.93-2.1 2)	0.109	1.16(0.74-1.8 2)	0.50 6	1.18(0.75-1.8 7)	0.467
using origina	non vs mild cSVD burden									
l data	low	47/163	reference	-	reference	-	reference	-	reference	-
	middle	139/32 8	1.81(1.21-2.7 2)	0.004	1.81(1.16-2.8 3)	0.010	1.56(0.96-2.5 3)	0.07 6	1.60(0.97-2.6 4)	0.064
	high	66/155	1.83(1.15-2.9 1)	0.011	2.06(1.22-3.4 8)	0.007	1.75(0.99-3.0 9)	0.05 2	1.85(1.03-3.3 0)	0.038
	non vs severe cSVD burden									
	low	52/168	reference	-	reference	-	reference	-	reference	-
	middle	102/29 1	1.20(0.80-1.8 1)	0.371	1.20(0.74-1.9 6)	0.454	1.01(0.59-1.7 1)	0.97 7	0.93(0.54-1.6 3)	0.809

Table2. Sensitivity analysis for the estimated association between variability of BP and cSVD burden

high	69/158	1.73(1.10-2.7 2)	0.018	2.01(1.15-3.5 1)	0.014	1.51(0.82-2.7 7)	0.18 3	1.70(0.90-3.2 2)	0.101
VIM of DBP									
non <i>vs</i> mild cSVD burden									
low	109/21 7	reference	-	reference	-	reference	-	reference	-
middle	204/40 1	1.03(0.74-1.4 3)	0.879	0.93(0.66-1.3 2)	0.695	0.84(0.58-1.2 2)	0.36 1	0.81(0.55-1.1 8)	0.271
high	102/19 1	1.14(0.77-1.6 8)	0.522	0.93(0.62-1.4 0)	0.735	0.89(0.57-1.4 0)	0.62 2	0.93(0.59-1.4 6)	0.742
non <i>vs</i> mild cSVD burden									
low	54/162	reference	-	reference	-	reference	-	reference	-
middle	138/33 5	1.40(0.95-2.0 7)	0.092	1.21(0.78-1.8 8)	0.388	1.05(0.66-1.6 8)	0.84 5	0.98(0.60-1.6 0)	0.943
high	60/149	1.35(0.85-2.1 4)	0.205	0.97(0.58-1.6 4)	0.917	0.94(0.54-1.6 5)	0.82 8	1.02(0.57-1.8 2)	0.955
non vs severe cSVD burden									
low	44/152	reference	-	reference	-	reference	-	reference	-
middle	112/30 9	1.40(0.92-2.1 2)	0.120	1.24(0.75-2.0 5)	0.395	1.05(0.61-1.7 9)	0.86 8	0.99(0.56-1.7 4)	0.973
high	67/156	1.85(1.15-2.9 6)	0.011	1.34(0.75-2.3 7)	0.321	1.23(0.66-2.3 0)	0.51 3	1.44(0.75-2.7 5)	0.272
VIM of PP									

non vs mild cSVD burden

	low	103/21 4	reference	-	reference	-	reference	-	reference	-
	middle	206/41 3	1.07(0.77-1.4 9)	0.678	1.02(0.72-1.4 4)	0.923	0.88(0.60-1.2 8)	0.49 1	0.87(0.60-1.2 7)	0.478
	high	106/18 2	1.50(1.01-2.2 4)	0.045	1.54(1.01-2.3 5)	0.044	1.37(0.86-2.1 8)	0.18 3	1.37(0.86-2.1 9)	0.184
	non <i>vs</i> mild cSVD burden									
	low	53/164	reference	-	reference	-	reference	-	reference	-
	middle	123/33 0	1.24(0.84-1.8 5)	0.279	1.09(0.70-1.6 9)	0.698	0.93(0.58-1.4 9)	0.75 3	0.93(0.58-1.5 0)	0.765
	high	76/152	2.09(1.33-3.3 0)	0.001	2.02(1.21-3.3 8)	0.007	1.64(0.94-2.8 8)	0.08 2	1.68(0.95-2.9 5)	0.073
	non vs severe cSVD burden									
	low	42/153	reference	-	reference	-	reference	-	reference	-
	middle	114/32 1	1.46(0.95-2.2 2)	0.082	1.22(0.74-2.0 1)	0.435	1.09(0.63-1.8 6)	0.76 0	1.18(0.67-2.0 6)	0.570
	high	67/143	2.33(1.44-3.7 8)	0.001	2.13(1.19-3.8 0)	0.011	1.76(0.94-3.3 1)	0.07 7	2.16(1.13-4.1 4)	0.020
	VIM of SBP									
	non vs mild cSVD burden									
no diabetes	low	89/199	reference	-	reference	-	reference	-	reference	-
no diabetes	middle	191/36 5	1.36(0.96-1.9 2)	0.085	1.34(0.94-1.9 3)	0.107	1.34(0.93-1.9 3)	0.12 2	1.36(0.93-1.9 8)	0.111
	high	88/165	1.41(0.93-2.1	0.102	1.54(1.00-2.3	0.052	1.43(0.91-2.2	0.12	1.43(0.91-2.2	0.124

		4)		9)		3)	2	6)	
non vs mild cSVD burden									
low	40/150	reference	-	reference	-	reference	-	reference	-
middle	104/27 8	1.64(1.06-2.5 4)	0.025	1.58(0.98-2.5 6)	0.062	1.44(0.88-2.3 6)	0.14 5	1.46(0.88-2.4 2)	0.14 ⁻
high	50/127	1.79(1.07-2.9 7)	0.025	2.12(1.20-3.7 5)	0.010	1.84(1.02-3.3 1)	0.04 2	1.98(1.08-3.6 1)	0.02
non vs severe cSVD burden									
low	33/143	reference	-	reference	-	reference	-	reference	-
middle	69/243	1.32(0.82-2.1 3)	0.253	1.22(0.70-2.1 3)	0.483	1.06(0.60-1.8 9)	0.84 1	0.97(0.53-1.7 9)	0.93
high	60/137	2.60(1.55-4.3 5)	<0.00 1	3.12(1.67-5.8 0)	<0.00 1	2.42(1.26-4.6 3)	0.00 8	2.68(1.35-5.3 3)	0.00
VIM of DBP									
non <i>vs</i> mild cSVD burden									
low	99/202	reference	-	reference	-	reference	-	reference	-
middle	180/35 4	1.08(0.76-1.5 2)	0.677	1.04(0.73-1.4 8)	0.837	1.00(0.69-1.4 4)	0.99 7	0.96(0.67-1.3 9)	0.83
high	89/173	1.10(0.73-1.6 5)	0.638	0.98(0.64-1.4 9)	0.911	0.97(0.63-1.5 0)	0.89 1	0.97(0.62-1.5 0)	0.87
non <i>vs</i> mild cSVD burden									
low	44/147	reference	-	reference	-	reference	-	reference	-
middle	103/27	1.39(0.90-2.1 3)	0.136	1.30(0.81-2.0 9)	0.274	1.22(0.75-1.9 8)	0.42	1.14(0.70-1.8 8)	0.59 [.]

high	47/131	1.31(0.79-2.1 6)	0.292	1.05(0.60-1.8 5)	0.854	1.03(0.58-1.8 3)	0.92 1	1.07(0.59-1.9 4)	0.820
non vs severe cSVD burden									
low	31/134	reference	-	reference	-	reference	-	reference	-
middle	83/257	1.58(0.98-2.5 6)	0.060	1.48(0.85-2.5 8)	0.167	1.36(0.76-2.4 3)	0.29 4	1.21(0.67-2.2 0)	0.533
high	48/132	1.90(1.11-3.2 4)	0.019	1.46(0.78-2.7 6)	0.241	1.39(0.72-2.6 9)	0.32 3	1.51(0.76-2.9 8)	0.236
VIM of PP									
non vs mild cSVD burden									
low	89/194	reference	-	reference	-	reference	-	reference	-
middle	190/38 1	1.17(0.83-1.6 6)	0.365	1.09(0.76-1.5 7)	0.625	1.09(0.76-1.5 8)	0.63 7	1.10(0.76-1.6 0)	0.607
high	89/154	1.62(1.05-2.4 8)	0.028	1.66(1.06-2.6 0)	0.028	1.65(1.04-2.6 2)	0.03 3	1.69(1.06-2.6 9)	0.026
non vs mild cSVD burden									
low	42/147	reference	-	reference	-	reference	-	reference	-
middle	98/289	1.28(0.83-1.9 8)	0.260	1.13(0.70-1.8 3)	0.610	1.18(0.72-1.9 3)	0.50 1	1.23(0.75-2.0 2)	0.414
high	54/119	2.08(1.25-3.4 5)	0.005	2.10(1.18-3.7 3)	0.012	2.17(1.20-3.9 3)	0.01 0	2.31(1.27-4.2 1)	0.006
non vs severe cSVD burden									
low	31/136	reference	-	reference	-	reference	-	reference	-
middle	77/268	1.37(0.84-2.2	0.204	1.17(0.67-2.0	0.591	1.27(0.71-2.2	0.41	1.47(0.80-2.7	0.213

			1)		4)		7)	4	0)	
	high	54/119	2.81(1.64-4.8	<0.00	2.63(1.38-5.0	0.003	2.81(1.43-5.5	0.00	3.51(1.73-7.1	<0.00
	nign	54/119	3)	1	3)	0.003	1)	3	0)	1
	VIM of SBP									
	non vs mild cSVD burden									
	low	81/179	reference	-	reference	-	reference	-	reference	-
	middle	147/30	1.10(0.76-1.6	0.598	1.15(0.79-1.6	0.461	1.16(0.78-1.7	0.46	1.19(0.80-1.7	0.395
	middle	8	0)	0.596	9)	0.401	2)	8	8)	0.395
	hinh	74/440	1.19(0.77-1.8	0 400	1.22(0.77-1.9	0 400	1.13(0.70-1.8	0.61	1.15(0.71-1.8	0.504
	high	71/143	5)	0.432	3)	0.403	2)	9	7)	0.564
	non vs mild cSVD burden									
un a sustilar un aut	low	27/125	reference	-	reference	-	reference	-	reference	-
no antihypert		74/005	1.67(1.00-2.7	0.040	1.86(1.06-3.2	0.00	1.73(0.97-3.0	0.06	1.81(1.01-3.2	0.047
ensive medi	middle	74/235	7)	0.048	6)	0.03	8)	2	6)	0.047
cations user		00///0	1.91(1.07-3.4		2.01(1.05-3.8		1.74(0.88-3.4		1.90(0.96-3.7	0.007
S	high	38/110	2)	0.028	5)	0.036	3)	0.11	7)	0.067
	non vs severe cSVD burden									
	low	24/122	reference	-	reference	-	reference	-	reference	-
		40/004	1.09(0.62-1.9	0 704	1.25(0.66-2.4	0.404	1.09(0.55-2.1	0.0	1.17(0.58-2.3	0.004
	middle	43/204	1)	0.761	0)	0.494	5)	0.8	8)	0.661
	hinh	07/00	1.53(0.82-2.8	0.404	1.60(0.76-3.3	0.044	1.07(0.48-2.3	0.86	1.42(0.63-3.2	0.404
	high	27/99	7)	0.184	6)	0.214	8)	1	1)	0.401
	VIM of DBP									
	11 OV (D. 1									

non vs mild cSVD burden

low	87/182	reference	-	reference	-	reference	-	reference	-
middle	147/31 4	0.96(0.67-1.3 9)	0.832	0.92(0.63-1.3 4)	0.66	0.92(0.63-1.3 6)	0.68 2	0.92(0.62-1.3 5)	0.657
high	65/134	1.03(0.66-1.6 1)	0.901	0.87(0.55-1.4 0)	0.569	0.89(0.55-1.4 4)	0.63 2	0.93(0.57-1.5 2)	0.783
non vs mild cSVD burden									
low	35/130	reference	-	reference	-	reference	-	reference	-
middle	74/241	1.20(0.75-1.9 3)	0.446	1.11(0.65-1.8 8)	0.699	1.02(0.59-1.7 4)	0.95 4	1.07(0.62-1.8 5)	0.812
high	30/99	1.18(0.66-2.1 0)	0.574	0.87(0.45-1.6 8)	0.674	0.85(0.43-1.6 8)	0.64 2	0.99(0.50-1.9 8)	0.978
non vs severe cSVD burden									
low	24/119								
middle	48/215	1.14(0.66-1.9 7)	0.646	1.06(0.56-2.0 1)	0.859	0.92(0.47-1.7 9)	0.81 3	0.96(0.49-1.8 9)	0.912
high	22/91	1.26(0.65-2.4 3)	0.487	0.92(0.42-1.9 9)	0.828	0.79(0.35-1.8 0)	0.57 9	1.03(0.45-2.3 8)	0.943
/IM of PP									
non vs mild cSVD burden									
low	74/167	reference	-	reference	-	reference	-	reference	-
middle	147/32 2	1.06(0.72-1.5 4)	0.778	0.99(0.67-1.4 7)	0.978	1.00(0.67-1.4 9)	0.98 9	1.01(0.68-1.5 0)	0.961
high	78/141	1.56(0.99-2.4 4)	0.055	1.44(0.90-2.3 0)	0.133	1.42(0.87-2.3 0)	0.16 1	1.45(0.89-2.3 7)	0.133

non <i>vs</i> mild cSVD burden									
low	24/117	reference	-	reference	-	reference	-	reference	-
middle	72/247	1.59(0.94-2.7	0.082	1.45(0.81-2.5	0.206	1.49(0.82-2.6	0.18	1.51(0.84-2.7	0.172
made	121271	0)	0.002	9)	0.200	9)	8	3)	0.172
high	43/106	2.64(1.46-4.7	0.001	2.19(1.12-4.2	0.021	2.02(1.02-4.0	0.04	2.13(1.07-4.2	0.031
ngn	43/100	9)	0.001	6)	0.021	2)	5	4)	0.001
non <i>vs</i> severe cSVD burden									
low	19/112	reference	-	reference	-	reference	-	reference	-
middle	47/222	1.31(0.73-2.3	0.363	1.21(0.61-2.4	0.582	1.45(0.71-2.9	0.30	1.51(0.72-3.1	0.276
made	411222	7)	0.505	0)	0.502	6)	9	4)	0.270
high	28/91	2.18(1.12-4.2	0.022	1.67(0.76-3.6	0.2	1.53(0.67-3.4	0.31	1.71(0.74-3.9	0.211
nign	20/91	3)	0.022	5)	0.2	9)	5	8)	0.211

Note:

multi adjusted OR₁: was adjusted age, gender, education level, drinking status, smoking status, physical activity level, baseline BMI, diabets, TG, HDL, and L DL level;

multi adjusted OR₂: based on the adjusted OR₁, and further adjusted mean value of SBP, DBP, or PP when the exposure was the corresponding variability of BP indicator.

BP variability was categorized into three groups (< p25 as low, p25-p75 as middle, or \geq p75 as high).

Abbreviations: VIM: variability independent of the mean; SBP: Systolic blood pressure; DBP: diastolic blood pressure; PP: pulse pressure; cSVD: cerebral s mall vessel disease; non-cSVD: if the total burden is zero; mild cSVD: if the total burden is one; moderate cSVD: if the total burden is 2; and severe cSVD: if the total burden is 3 or 4.

Outcomes	group	n/N	unadjusted OR (95%Cl)	<i>p</i> value	age- and gend er- adjusted O R (95%CI)	<i>p</i> value	multi adjusted OR₁(95%CI)	<i>p</i> value	multi adjusted OR ₂ (95%CI)	<i>p</i> value
using origin	nal data									
LA	VIM of SBF	כ								
	low	45/316	reference	-	reference	-	reference	-	reference	-
	middle	99/644	1.09(0.75-1.60)	0.645	1.04(0.69-1.57)	0.863	0.99(0.64-1.54)	0.966	0.89(0.56-1.40)	0.613
	high	68/324	1.60(1.06-2.42)	0.026	1.64(1.04-2.59)	0.034	1.39(0.85-2.29)	0.190	1.48(0.89-2.45)	0.132
	VIM of DBF	D								
	low	39/315	reference	-	reference	-	reference	-	reference	-
	middle	106/651	1.38(0.93-2.04)	0.113	1.32(0.86-2.03)	0.203	1.17(0.74-1.84)	0.510	1.16(0.73-1.85)	0.526
	high	67/318	1.89(1.23-2.90)	0.004	1.76(1.10-2.83)	0.019	1.59(0.96-2.65)	0.071	1.77(1.06-2.97)	0.030
	VIM of PP									
	low	39/309	reference	-	reference	-	reference	-	reference	-
	middle	108/650	1.38(0.93-2.05)	0.110	1.25(0.82-1.92)	0.296	1.20(0.77-1.88)	0.422	1.29(0.81-2.06)	0.276
	high	65/325	1.73(1.12-2.67)	0.013	1.48(0.92-2.37)	0.106	1.30(0.79-2.14)	0.302	1.56(0.93-2.60)	0.092
CMBs	VIM of SBF	C								
	low	87/316	reference	-	reference	-	reference	-	reference	-
	middle	168/644	0.93(0.69-1.26)	0.634	0.86(0.63-1.19)	0.373	0.78(0.55-1.10)	0.153	0.75(0.53-1.06)	0.104
	high	96/324	1.11(0.79-1.56)	0.557	1.06(0.73-1.53)	0.773	0.94(0.64-1.39)	0.754	0.97(0.65-1.44)	0.873
	VIM of DBF	C								

Table 3. Sensitivity analysis for the estimated association between variability of BP and different markers of cSVD

	low	78/315	reference	-	reference	-	reference	-	reference	-
	middle	175/651	1.12(0.82-1.52)	0.483	1.02(0.73-1.42)	0.909	0.95(0.67-1.34)	0.766	0.93(0.66-1.32)	0.694
	high	98/318	1.35(0.95-1.92)	0.090	1.16(0.80-1.69)	0.440	1.09(0.73-1.62)	0.683	1.15(0.77-1.72)	0.492
	VIM of PP									
	low	78/309	reference	-	reference	-	reference	-	reference	-
	middle	171/650	1.06(0.78-1.44)	0.725	0.94(0.67-1.31)	0.708	0.85(0.60-1.21)	0.370	0.86(0.61-1.23)	0.412
	high	102/325	1.35(0.96-1.92)	0.087	1.14(0.79-1.66)	0.484	1.06(0.72-1.57)	0.770	1.12(0.76-1.67)	0.559
WMH	VIM of SB	C								
	low	73/316	reference	-	reference	-	reference	-	reference	-
	middle	181/644	1.30(0.95-1.78)	0.099	1.25(0.89-1.75)	0.198	1.17(0.81-1.68)	0.408	1.11(0.77-1.60)	0.583
	high	92/324	1.32(0.92-1.88)	0.126	1.22(0.83-1.80)	0.315	1.06(0.70-1.61)	0.779	1.07(0.70-1.63)	0.758
	VIM of DBI									
	low	78/315	reference	-	reference	-	reference	-	reference	-
	middle	179/651	1.15(0.85-1.57)	0.368	1.03(0.74-1.44)	0.863	0.95(0.67-1.36)	0.791	0.93(0.65-1.34)	0.710
	high	89/318	1.18(0.83-1.68)	0.357	0.91(0.61-1.34)	0.624	0.83(0.54-1.25)	0.371	0.86(0.56-1.32)	0.495
	VIM of PP									
	low	72/309	reference	-	reference	-	reference	-	reference	-
	middle	175/650	1.21(0.88-1.66)	0.231	1.04(0.74-1.47)	0.821	0.95(0.66-1.37)	0.786	0.98(0.67-1.42)	0.905
	high	99/325	1.44(1.01-2.05)	0.043	1.15(0.78-1.69)	0.487	1.03(0.68-1.55)	0.892	1.10(0.73-1.68)	0.642
PVS	VIM of SB	D								
	low	175/316	reference	-	reference	-	reference	-	reference	-
	middle	395/644	1.28(0.97-1.68)	0.078	1.25(0.92-1.71)	0.156	1.13(0.81-1.59)	0.473	1.14(0.80-1.62)	0.462
	high	215/324	1.59(1.15-2.19)	0.005	1.74(1.20-2.52)	0.003	1.55(1.04-2.32)	0.030	1.63(1.08-2.46)	0.020
	VIM of DBI	D								

	low	173/315	reference	-	reference	-	reference	-	reference	-
	middle	405/651	1.35(1.03-1.77)	0.030	1.22(0.89-1.66)	0.215	1.16(0.83-1.61)	0.387	1.12(0.79-1.58)	0.530
	high	207/318	1.53(1.11-2.11)	0.009	1.22(0.84-1.76)	0.301	1.27(0.85-1.88)	0.243	1.38(0.91-2.09)	0.128
	VIM of PP									
	low	169/309	reference	-	reference	-	reference	-	reference	-
	middle	393/650	1.27(0.96-1.67)	0.090	1.14(0.83-1.56)	0.411	1.05(0.75-1.48)	0.757	1.06(0.75-1.49)	0.749
	high	223/325	1.81(1.31-2.50)	<0.001	1.75(1.20-2.54)	0.003	1.58(1.05-2.37)	0.028	1.62(1.08-2.45)	0.021
no diabete	es									
LA	VIM of SBF	C								
	low	31/272	reference	-	reference	-	reference	-	reference	-
	middle	66/538	1.09(0.69-1.71)	0.719	0.97(0.60-1.58)	0.906	0.89(0.54-1.46)	0.633	0.78(0.46-1.31)	0.347
	high	54/275	1.90(1.18-3.06)	0.009	1.87(1.11-3.16)	0.019	1.59(0.92-2.73)	0.095	1.64(0.93-2.89)	0.086
	VIM of DBF	C								
	low	27/277	reference	-	reference	-	reference	-	reference	-
	middle	77/540	1.54(0.97-2.45)	0.069	1.44(0.88-2.37)	0.145	1.40(0.84-2.33)	0.201	1.29(0.76-2.17)	0.343
	high	47/268	1.97(1.19-3.27)	0.009	1.78(1.03-3.08)	0.038	1.71(0.97-2.99)	0.062	1.82(1.02-3.24)	0.041
	VIM of PP									
	low	31/267	reference	-	reference	-	reference	-	reference	-
	middle	72/556	1.13(0.72-1.77)	0.587	1.04(0.64-1.68)	0.876	1.12(0.68-1.83)	0.660	1.22(0.73-2.04)	0.445
	high	48/262	1.71(1.05-2.78)	0.032	1.41(0.82-2.40)	0.212	1.46(0.84-2.55)	0.178	1.72(0.97-3.05)	0.062
CMBs	VIM of SBF	C								
	low	59/272	reference	-	reference	-	reference	-	reference	-
	middle	125/538	1.09(0.77-1.55)	0.621	1.00(0.69-1.45)	0.983	0.95(0.65-1.39)	0.803	0.93(0.64-1.36)	0.706
	high	81/275	1.51(1.02-2.22)	0.038	1.41(0.93-2.14)	0.101	1.29(0.85-1.98)	0.235	1.31(0.85-2.02)	0.215

VIM of DBF	C								
low	60/277	reference	-	reference	-	reference	-	reference	-
middle	131/540	1.16(0.82-1.64)	0.406	1.06(0.74-1.53)	0.739	1.04(0.72-1.51)	0.821	1.01(0.69-1.47)	0.961
high	74/268	1.38(0.93-2.04)	0.107	1.18(0.78-1.80)	0.426	1.14(0.75-1.74)	0.546	1.18(0.77-1.81)	0.443
VIM of PP									
low	54/267	reference	-	reference	-	reference	-	reference	-
middle	129/556	1.19(0.83-1.70)	0.337	1.09(0.75-1.59)	0.654	1.10(0.75-1.62)	0.615	1.15(0.78-1.70)	0.484
high	82/262	1.80(1.21-2.67)	0.004	1.55(1.02-2.38)	0.042	1.58(1.02-2.44)	0.039	1.66(1.07-2.58)	0.023
VIM of SBF	D								
low	55/272	reference	-	reference	-	reference	-	reference	-
middle	132/538	1.28(0.90-1.83)	0.169	1.18(0.81-1.73)	0.396	1.10(0.74-1.63)	0.638	1.05(0.70-1.56)	0.820
high	81/275	1.65(1.11-2.44)	0.013	1.54(1.00-2.37)	0.050	1.34(0.86-2.10)	0.193	1.33(0.85-2.10)	0.216
VIM of DBF	C								
low	62/277	reference	-	reference	-	reference	-	reference	-
middle	138/540	1.19(0.85-1.68)	0.318	1.08(0.74-1.56)	0.693	0.99(0.68-1.45)	0.962	0.94(0.64-1.39)	0.769
high	68/268	1.18(0.79-1.75)	0.413	0.95(0.61-1.46)	0.801	0.90(0.58-1.40)	0.646	0.92(0.59-1.45)	0.732
/IM of PP									
low	57/267	reference	-	reference	-	reference	-	reference	-
middle	131/556	1.14(0.80-1.62)	0.479	1.00(0.68-1.47)	0.990	1.02(0.69-1.51)	0.925	1.08(0.72-1.61)	0.708
high	80/262	1.62(1.09-2.40)	0.016	1.32(0.85-2.04)	0.211	1.30(0.83-2.03)	0.255	1.39(0.88-2.20)	0.153
VIM of SBF	D								
low	141/272	reference	-	reference	-	reference	-	reference	-
middle	315/538	1.31(0.98-1.76)	0.069	1.27(0.92-1.77)	0.151	1.21(0.86-1.70)	0.267	1.21(0.85-1.72)	0.293
high	178/275	1.70(1.21-2.40)	0.002	1.84(1.24-2.72)	0.002	1.64(1.09-2.45)	0.017	1.69(1.11-2.57)	0.015

WMH

PVS

	VIM of DBF	D C								
	low	145/277	reference	-	reference	-	reference	-	reference	-
	middle	326/540	1.39(1.04-1.86)	0.028	1.30(0.94-1.81)	0.113	1.27(0.91-1.77)	0.165	1.20(0.85-1.70)	0.290
	high	163/268	1.41(1.01-1.99)	0.046	1.19(0.81-1.75)	0.386	1.19(0.80-1.76)	0.399	1.23(0.82-1.85)	0.326
	VIM of PP									
	low	140/267	reference	-	reference	-	reference	-	reference	-
	middle	321/556	1.24(0.92-1.66)	0.152	1.14(0.82-1.58)	0.443	1.17(0.83-1.64)	0.365	1.21(0.85-1.70)	0.289
	high	173/262	1.76(1.24-2.50)	0.002	1.69(1.13-2.53)	0.011	1.69(1.12-2.55)	0.013	1.77(1.16-2.71)	0.008
no antihy	pertensive me	dications u	sers							
LA	VIM of SBF	þ								
	low	17/230	reference	-	reference	-	reference	-	reference	-
	middle	38/425	1.23(0.68-2.23)	0.496	1.26(0.67-2.36)	0.466	1.18(0.61-2.28)	0.625	1.22(0.63-2.37)	0.557
	high	24/208	1.63(0.85-3.14)	0.14	1.61(0.80-3.23)	0.179	1.22(0.58-2.58)	0.604	1.49(0.71-3.13)	0.293
	VIM of DBF	D								
	low	18/241	reference	-	reference	-	reference	-	reference	-
	middle	40/436	1.25(0.70-2.23)	0.449	1.24(0.67-2.28)	0.497	1.14(0.60-2.17)	0.683	1.19(0.63-2.28)	0.589
	high	21/186	1.58(0.81-3.05)	0.177	1.58(0.77-3.21)	0.21	1.42(0.67-3.01)	0.359	1.70(0.79-3.62)	0.172
	VIM of PP									
	low	15/210	reference	-	reference	-	reference	-	reference	-
	middle	42/441	1.37(0.74-2.53)	0.317	1.35(0.70-2.58)	0.371	1.66(0.84-3.30)	0.145	1.67(0.84-3.32)	0.145
	high	22/212	1.50(0.76-2.99)	0.243	1.19(0.57-2.49)	0.636	1.10(0.51-2.41)	0.804	1.17(0.54-2.53)	0.693
CMBs	VIM of SBF	0								
	low	51/230	reference	-	reference	-	reference	-	reference	-
	middle	89/425	0.93(0.63-1.37)	0.713	0.92(0.61-1.38)	0.686	0.90(0.59-1.36)	0.609	0.91(0.60-1.39)	0.672

	high	48/208	1.05(0.67-1.65)	0.821	0.96(0.60-1.55)	0.881	0.87(0.53-1.42)	0.58	0.94(0.58-1.54)	0.808
	VIM of DB	Ρ								
	low	51/241	reference	-	reference	-	reference	-	reference	-
	middle	90/436	0.97(0.66-1.43)	0.873	0.91(0.61-1.36)	0.644	0.87(0.58-1.31)	0.509	0.89(0.59-1.34)	0.573
	high	47/186	1.26(0.80-1.98)	0.317	1.09(0.67-1.77)	0.721	1.00(0.61-1.64)	0.999	1.09(0.66-1.78)	0.739
	VIM of PP									
	low	46/210	reference	-	reference	-	reference	-	reference	-
	middle	89/441	0.90(0.60-1.35)	0.612	0.80(0.52-1.22)	0.298	0.82(0.53-1.26)	0.355	0.81(0.53-1.25)	0.344
	high	53/212	1.19(0.76-1.87)	0.453	0.93(0.57-1.50)	0.764	0.89(0.54-1.46)	0.643	0.90(0.55-1.47)	0.678
WMH	VIM of SBI	Þ								
	low	39/230	reference	-	reference	-	reference	-	reference	-
	middle	92/425	1.35(0.89-2.05)	0.153	1.41(0.90-2.20)	0.129	1.31(0.83-2.06)	0.248	1.34(0.84-2.13)	0.214
	high	41/208	1.20(0.74-1.95)	0.457	1.10(0.66-1.86)	0.711	0.90(0.52-1.55)	0.706	0.99(0.57-1.72)	0.979
	VIM of DBI	Р								
	low	52/241	reference	-	reference	-	reference	-	reference	-
	middle	89/436	0.93(0.63-1.37)	0.721	0.85(0.56-1.29)	0.452	0.77(0.50-1.18)	0.229	0.80(0.52-1.23)	0.309
	high	31/186	0.73(0.44-1.19)	0.205	0.56(0.33-0.97)	0.037	0.52(0.30-0.91)	0.021	0.57(0.33-1.00)	0.048
	VIM of PP									
	low	35/210	reference	-	reference	-	reference	-	reference	-
	middle	86/441	1.21(0.79-1.87)	0.385	1.10(0.69-1.76)	0.675	1.14(0.71-1.83)	0.583	1.16(0.72-1.88)	0.541
	high	51/212	1.58(0.98-2.56)	0.061	1.24(0.74-2.09)	0.419	1.13(0.66-1.93)	0.662	1.19(0.69-2.05)	0.535
PVS	VIM of SBI	Þ								
	low	111/230	reference	-	reference	-	reference	-	reference	-
	middle	218/425	1.13(0.82-1.56)	0.459	1.17(0.82-1.68)	0.384	1.12(0.77-1.62)	0.549	1.17(0.80-1.71)	0.424

high	124/208	1.58(1.08-2.31)	0.018	1.66(1.08-2.55)	0.021	1.49(0.96-2.33)	0.077	1.64(1.04-2.58)	0.034	
VIM of DBP)									
low	117/241	reference	-	reference	-	reference	-	reference	-	
middle	232/436	1.21(0.88-1.65)	0.245	1.15(0.81-1.63)	0.443	1.12(0.78-1.60)	0.552	1.14(0.79-1.66)	0.474	
high	104/186	1.34(0.92-1.97)	0.131	1.15(0.74-1.78)	0.543	1.18(0.75-1.85)	0.475	1.34(0.84-2.13)	0.222	
VIM of PP										
low	94/210	reference	-	reference	-	reference	-	reference	-	
middle	231/441	1.36(0.98-1.89)	0.07	1.27(0.88-1.83)	0.206	1.29(0.88-1.87)	0.19	1.30(0.89-1.89)	0.178	
high	128/212	1.88(1.28-2.77)	0.001	1.63(1.05-2.53)	0.031	1.57(0.99-2.47)	0.053	1.64(1.04-2.59)	0.034	
										_

Note:


multi adjusted OR₁: was adjusted age, gender, education level, drinking status, smoking status, physical activity level, baseline BMI, diabets, TG, HDL, and L DL level;

multi adjusted OR₂: based on the adjusted OR₁, and further adjusted mean value of SBP, DBP, or PP when the exposure was the corresponding variability of BP indicator;

BP variability was categorized into three groups (< p25 as low, p25-p75 as middle, or \geq p75 as high).

Abbreviations:VIM: variability independent of the mean; LA: lacunes; CMBs: cerebral microbleeds; PVS: enlarged perivascular spaces; WMH: white matter h yperintensities; SBP: Systolic blood pressure; DBP: diastolic blood pressure; PP: pulse pressure; cSVD: cerebral small vessel disease; non-cSVD: if the tota burden is zero; mild cSVD: if the total burden is one; moderate cSVD: if the total burden is 2; and severe cSVD: if the total burden is 3 or 4.

A total of 1508 participants completed brain MR imaging between December 2020 and March 2022





cSVD: no VS mild Low 101/217 Middle 214/403 High 100/189 cSVD: no VS moderate Low 47/163 Middle 139/328 High 66/155 CSVD: no VS severe Low 52/168	1.29(0.90-1.85) 1.27(0.82-1.94)		<i>p</i> value - 0.163 0.281	109/217 204/401	Adjusted OR(95%CI) reference 0.91(0.64-1.30)		p value		Adjusted OR(95%CI)		p value
Low 101/217 n Middle 214/403 1 High 10/1218 1 CSVD: no VS moderate 2 1 Low 47/163 n Middle 139/328 1 High 66/155 1 CSVD: no VS severe 2 Low 52/168	1.29(0.90-1.85) 1.27(0.82-1.94) reference 1.66(1.03-2.65)		0.281	204/401	0.91(0.64-1.30)	. † .					
Middle 214/403 1 High 100/189 1 cSVD: no VS moderate 1 1 Low 47/163 n Middle 139/328 1 High 66/55 1 cSVD: no VS severe 1 Low 52/168 n	1.29(0.90-1.85) 1.27(0.82-1.94) reference 1.66(1.03-2.65)	8 ; + −−1 8 ; + −−1	0.281	204/401	0.91(0.64-1.30)	. †					
High 100/189 1 cSVD: no VS moderate Low 47/163 n Middle 139/328 1 High 66/155 1 CSVD: no VS severe Low 52/168 n	1.27(0.82-1.94) reference 1.66(1.03-2.65)		0.281				-		reference	•	-
cSVD: no VS moderate Low 47/163 Middle 139/328 High 66/155 CSVD: no VS severe Low 52/168	reference 1.66(1.03-2.65)			102/191			0.615	206/413	0.99(0.69-1.40)	₽ ₩₩	0.935
Low 47/163 n Middle 139/328 1 High 66/155 1 cSVD: no VS severe Low 52/168	1.66(1.03-2.65)				0.98(0.64-1.50)	I IIIIIIIII	0.943	106/182	1.48(0.96-2.28)		0.073
Middle 139/328 1 High 66/155 1 cSVD: no VS severe 5 1 Low 52/168 n	1.66(1.03-2.65)						-				
High 66/155 1 cSVD: no VS severe Low 52/168 re				54/162	reference	+		53/164	reference	+	-
cSVD: no VS severe Low 52/168 m	1.89(1.09-3.29)		0.036	138/335	1.09(0.69-1.73)		0.708	123/330	1.12(0.71-1.76)		0.634
Low 52/168 m		→	0.023	60/149	1.01(0.58-1.75)		0.973	76/152	1.99(1.17-3.41)		0.012
	reference		-	44/152	reference	+		42/153	reference	+	-
Middle 102/291 0	0.94(0.56-1.59)		0.814	112/309	1.04(0.61-1.76)		0.888	114/321	1.38(0.81-2.35)	I →→→→I	0.232
High 69/158 1	1.75(0.96-3.20)		0.067	67/156	1.39(0.76-2.55)	₽┼-₽₽	0.292	67/143	2.49(1.34-4.63)	· · · · · · · · · · · · · · · · · · ·	0.004
LA: no VS yes			1				:				
Low 45/316 m	reference	1	- 1	39/315	reference	+	-	39/309	reference	+	-
Middle 99/644 0	0.86(0.55-1.32)	8-0B	0.485	106/651	1.17(0.75-1.82)		0.492	108/650	1.42(0.91-2.22)	8	0.124
High 68/324 1	1.55(0.95-2.51)	—	0.076	67/318	1.74(1.06-2.84)	→ → →	0.028	65/325	1.75(1.06-2.89)	}	0.028
CMBs: no VS yes											
Low 87/316 m	reference		-	78/315	reference	+		78/309	reference	+	-
Middle 168/644 0	0.79(0.57-1.10)	14-I	0.158	175/651	0.96(0.69-1.34)	₽-1	0.812	171/650	0.96(0.68-1.34)	8-6-8	0.793
High 96/324 1	1.00(0.69-1.47)	→	0.985	98/318	1.16(0.79-1.70)	8-148	0.457	102/325	1.19(0.81-1.75)	8448	0.367
WMH: no VS yes			1								
Low 73/316 m	reference		-	78/315	reference	+	-	72/309	reference	•	-
Middle 181/644 1	1.09(0.77-1.55)	-	0.622	179/651	0.91(0.64-1.28)	8-48	0.582	175/650	1.08(0.75-1.54)	H	0.679
High 92/324 1	1.09(0.73-1.64)		0.672	89/318	0.87(0.58-1.31)	8-4-8	0.510	99/325	1.19(0.79-1.78)	8-148	0.408
PVS: no VS yes	. ,		1				-				
Low 175/316 m	reference	1	-	173/315	reference	+	-	169/309	reference	+	-
Middle 395/644 1	1.19(0.85-1.65)	0	0.312	405/651	1.15(0.83-1.59)	pip-q	0.398	393/650	1.17(0.85-1.61)	lite-l	0.348
	1.62(1.10-2.39)		0.015	207/318	1.29(0.88-1.91)	8	0.194	223/325	1.77(1.20-2.61)		0.004
		1 1.5 3	5				5			1.5 3	5

Age < 60 years old

Age ≥ 60 years old

							9		
SBP variability	Groups	n/N	Adjusted OR(95%CI)		p value	n/N	Adjusted OR(95%CI)		p value
	cSVD: no VS mild								
	Low	70/179	reference		-	31/38	reference		-
	Middle High cSVD: no VS moderate	143/317 67/152	1.29(0.88-1.90) 1.23(0.77-1.95)	₿ <mark>₩₽₩₩</mark> ₽ ₽₩₽₩₽₩₽	0.194 0.387	71/86 33/37	1.34(0.45-4.03) 2.90(0.69-12.11)		0.602 • 0.145
	Low	21/130	reference		-	26/33	reference		-
	Middle High cSVD: no VS severe	54/228 23/108	1.58(0.87-2.85) 1.59(0.78-3.25)		0.133 0.203	85/100 43/47	1.87(0.61-5.76) 4.87(1.14-20.83)		0.2750.033
	Low	11/120	reference		-	41/48	reference		-
	Middle High LA: no VS yes	25/199 13/98	1.25(0.55-2.84) 1.68(0.64-4.43)		0.594 0.294	77/92 56/60	0.85(0.27-2.67) 3.87(0.90-16.74)		0.782 • 0.070
	Low	13/211	reference		-	32/105	reference		-
	Middle High C MBs: no VS yes	28/396 17/188	1.02(0.49-2.14) 1.83(0.78-4.29)		0.955 0.162	71/248 51/136	0.76(0.44-1.31) 1.36(0.75-2.49)		0.322 0.314
	Low	35/211	reference		-	52/105	reference		-
	Middle High	66/396 30/188	0.93(0.58-1.48) 0.92(0.52-1.61)		0.751 0.765	102/248 66/136	0.63(0.39-1.02) 0.97(0.56-1.67)		0.061 0.903
	WMH: no VS yes	30/100	0.32(0.32-1.01)		0.705				
	Low	24/211	reference		-	49/105	reference 0.90(0.55-1.47)		- 0.678
	Middle High	64/396 23/188	1.34(0.79-2.27) 1.01(0.53-1.92)		0.271 0.983		1.13(0.65-1.96)		0.659
	PVS: no VS yes					04/405	reference		
	LOW Middle	81/211 181/396	reference 1.38(0.95-2.00)		- 0.094	94/105 214/248	0.65(0.30-1.42)		- 0.278
	High	90/188	1.65(1.06-2.58)		0.027	125/136	1.70(0.66-4.38)		0.275
DDD				0 1 1.5 3	5		0	1 1.5 3	5
DBP variability	Groups	n/N	Adjusted OR(95%CI)		p value	n/N	Adjusted OR(95%CI)		p value
	cSVD: no VS mild Low	80/183	reference	•	-	29/34	reference	٠	-
	Middle	140/326	0.92(0.63-1.34)	₽ ₽ −0	0.673	64/75	0.97(0.29-3.27)	I	0.957
	High cSVD: no VS moderate	60/139	1.03(0.65-1.63)		0.905	42/52	0.77(0.21-2.81)		0.695
	Low	23/126	reference	+	-	31/36	reference	+	-
	Middle	55/241	1.16(0.65-2.06)	0 0	0.618	83/94	1.06(0.31-3.61)		0.928
	High cSVD: no VS severe	20/99	1.26(0.62-2.56)		0.528	40/50	0.67(0.18-2.50)		0.555
	Low	14/117	reference		-	30/35	reference		-
	Middle High	26/212 9/88	0.89(0.41-1.94) 0.98(0.36-2.66)		0.779 0.975	86/97 58/68	1.19(0.34-4.13) 1.26(0.34-4.74)		0.784 0.730
	LA: no VS yes								• • • • • •
	Low Middle	16/220 31/407	reference 0.97(0.48-1.93)	+	-	23/95 75/244	reference 1.34(0.75-2.39)	+	- 0.325
	High	11/168	0.96(0.40-2.30)		0.920 0.920	56/150	2.37(1.26-4.45)		0.007
	CMBs: no VS yes	20/000				40/05			
	Low Middle	38/220 64/407	reference 0.84(0.53-1.32)		- 0.447	40/95 111/244	reference 1.16(0.70-1.91)		- 0.570
	High	29/168	1.11(0.64-1.92)		0.722	69/150	1.29(0.75-2.24)	₽ - ++	0.361
	WMH: no VS yes Low	32/220	reference	•	-	46/95	reference		-
	Middle	59/407	0.89(0.55-1.45)	8−− 1	0.640	120/244	0.95(0.58-1.56)		0.838
	High PVS: no VS yes	20/168	0.83(0.45-1.55)	B	0.561	69/150	0.98(0.57-1.70)		0.944
	Low	90/220	reference	•	-	83/95	reference	•	-
	Middle High	187/407 75/168	1.16(0.81-1.67) 1.32(0.85-2.05)		0.407 0.223		1.15(0.53-2.49) 1.35(0.57-3.15)		0.732 0.495
PP variability	Groups	n/N	Adjusted OR(95%CI)	0 1 1.5 3	₅ p value	n/N	Adjusted OR(95%CI)	0 1 1.5 3	⁵ p value
	cSVD: no VS mild								
	Low Middle	78/183	reference 0.96(0.66-1.40)	.	- 0.846	25/31 71/85	reference 1.07(0.34-3.34)	÷	- 0.908
	High	67/137	1.48(0.92-2.36)		0.103	39/45	1.35(0.37-4.97)		0.908
	cSVD: no VS moderate	05/400				00/04			
	Low Middle	25/130 48/241	reference 1.18(0.67-2.07)	₽	- 0.573	28/34 75/89	reference 1.12(0.36-3.53)		- 0.846
	High	25/95	2.04(1.03-4.06)	· · · · · · · · · · · · · · · · · · ·	0.042	51/57	1.59(0.43-5.86)		• 0.483
	cSVD: no VS severe Low	12/117	reference	↓ ◆	-	30/36	reference	1	-
	Middle	21/214	1.16(0.52-2.58)		0.724	93/107	1.53(0.47-4.97)		0.482
	High LA: no VS yes	16/86	3.33(1.31-8.44)	•	0.011	51/57	1.84(0.48-7.02)		• 0.372
	Low	14/220	reference	+	-	25/89	reference		-
	Middle	25/397	1.18(0.57-2.43)		0.659	83/253	1.60(0.89-2.87)		0.115
	High CMBs: no VS yes	19/178	3.02(1.31-6.93)		0.009	46/147	1.42(0.75-2.69)		0.282
	Low	40/220	reference		-	38/89	reference		-
	Middle High	59/397 32/178	0.80(0.51-1.26) 1.01(0.58-1.75)		0.340 0.972		1.17(0.70-1.96) 1.40(0.80-2.45)	₽₽₽₽₽₽₽₽₽₽₽₽₽	0.541 0.240
	WMH: no VS yes								
	Low Middle	28/220 51/397	reference 1.05(0.63-1.75)		- 0.862	44/89 124/253	reference 1.07(0.64-1.80)	1	- 0.798
	High	32/178	1.61(0.89-2.91)	l	0.882	67/147	0.90(0.51-1.57)		0.798
	PVS: no VS yes Low	92/220	reference		-	77/00	reference		
	Low Middle		1.15(0.80-1.64)	1	- 0.452	77/89 223/253	reference 1.17(0.54-2.54)		- 0.688
	High	90/178	1.86(1.20-2.88)		0.006	133/147	1.49(0.63-3.57)		0.366
				0 1 1.5 3	5		0	1 1.5 3	5

Male

Female

SBP variability	Groups	n/N	Adjusted OR(95%CI)		p value	n/N	Adjusted OR(95%CI)	p value
	cSVD: no VS mild							
	Low	31/38	reference		-	44/107	reference	-
	Middle High	71/86 33/37	1.34(0.45-4.03) 2.90(0.69-12.11)		0.602 0.145	102/217 71/131	1.24(0.73-2.11)	0.422 0.119
	cSVD: no VS moderate						• •	
	Low Middle	26/33 85/100	reference		- 0.275	15/78 56/171	reference	- 0.117
	High	43/47	1.87(0.61-5.76) 4.87(1.14-20.83)		0.033	27/87	1.88(0.85-4.16) 2.00(0.84-4.76)	0.116
	cSVD: no VS severe		,		•			-
	Low Middle	41/48 77/92	reference 0.85(0.27-2.67)	1	- 0.782	11/74 20/135	reference 0.80(0.30-2.14)	- 0.652
	High	56/60	3.87(0.90-16.74)		0.782	20/135	2.39(0.87-6.54)	0.052
	LA: no VS yes							
	Low Middle	32/105 71/248	reference 0.76(0.44-1.31)	i a di a	- 0.322	11/133 14/293	reference 0.35(0.14-0.89)	- 0.027
	High	51/136	1.36(0.75-2.49)		0.314	21/180	1.44(0.59-3.50)	0.421
	CMBs: no VS yes							
	Low Middle	52/105 102/248	reference 0.63(0.39-1.02)	a.	- 0.061	32/133 49/293	reference 0.58(0.34-1.00)	- 0.049
	High	66/136	0.97(0.56-1.67)		0.903	40/180	0.88(0.50-1.56)	0.667
	WMH: no VS yes							
	Low Middle	49/105 117/248	reference 0.90(0.55-1.47)	<u>a</u> ia	- 0.678	19/133 68/293	reference 1.68(0.91-3.11)	- 0.099
	High		1.13(0.65-1.96)		0.659	37/180	1.52(0.78-2.97)	0.214
	PVS: no VS yes					=		
	Low Middle		reference 0.65(0.30-1.42)	وسأسور	- 0.278	54/133 145/293	reference	- 0.265
	High		1.70(0.66-4.38)		0.275		2.00(1.14-3.49)	0.015
DBP variability	Groups	n/N	Adjusted OR(95%Cl)	1 1.5 3	; p value	n/N	ن بانغ Adjusted OR(95%Cl)	; p value
	cSVD: no VS mild							
	Low	61/106	reference	•	-	48/111	reference	-
	Middle High	97/181 40/67	0.90(0.53-1.52) 0.93(0.48-1.83)		0.681 0.844		1.02(0.62-1.67) 1.00(0.57-1.76)	0.951 0.993
	cSVD: no VS moderate	40/01	0.00(0.40 1.00)		0.044	02/124		0.000
	Low	31/76	reference	•	-	23/86	reference	-
	Middle High	87/171 36/63	1.55(0.82-2.93) 1.46(0.66-3.23)		0.179 0.344	51/164 24/86	0.70(0.35-1.39) 0.57(0.25-1.28)	0.304 0.171
	cSVD: no VS severe							
	Low Middle	35/80 90/174	reference 1.34(0.68-2.64)	÷	- 0.394	9/72 22/135	reference	- 0.568
	High	90/1/4 45/72	1.50(0.66-3.44)		0.394	22/135	1.46(0.52-4.05)	- 0.471
	LA: no VS yes							
	Low Middle	30/172 87/358	reference 1.38(0.83-2.31)	÷	- 0.213	9/143 19/293	reference	- 0.474
	High	49/148	1.93(1.08-3.45)	}	0.027	18/170	1.53(0.60-3.94)	0.373
	CMBs: no VS yes	10/170				00/140		
	Low Middle	49/172 121/358	reference 1.21(0.78-1.86)		- 0.399	29/143 54/293	reference 0.73(0.43-1.25)	- 0.249
	High		1.42(0.85-2.38)	0 0	0.179	38/170	0.86(0.48-1.54)	0.610
	WMH: no VS yes Low	50/172	reference			28/143	reference	
	Middle		1.02(0.65-1.60)		0.922	59/293	0.74(0.42-1.29)	0.286
	High	52/148	0.93(0.54-1.59)		0.788	37/170	0.80(0.43-1.50)	0.492
	PVS: no VS yes Low	114/172	reference	•	-	59/143	reference	-
	Middle		1.15(0.73-1.83)	0-jo0	0.550	153/293	1.20(0.75-1.93)	0.444
	High	116/148	1.40(0.78-2.52)		0.261	91/170	1.18(0.69-2.02)	0.535
PP variability	Groups	n/N	Adjusted OR(95%CI)		p value	n/N	Adjusted OR(95%Cl)	p value
	cSVD: no VS mild							
	Low	62/112	reference		-			- 0.527
	Middle High	90/179 46/63	0.77(0.47-1.26) 1.68(0.82-3.44)		0.293 0.153		1.18(0.70-1.99) 1.32(0.74-2.37)	0.352
	cSVD: no VS moderate							
	Low Middle	37/87 74/163	reference 0.98(0.55-1.75)		- 0.945	16/77 49/167	reference	- 0.638
	High	43/60	1.90(0.86-4.19)		0.114	33/92	2.08(0.90-4.83)	0.087
	cSVD: no VS severe	05/05	,			7/00		
	Low Middle	35/85 88/177	reference 1.16(0.62-2.20)		- 0.640	7/68 26/144	reference	- 0.478
	High	47/64	1.96(0.84-4.60)		0.120	20/79	3.68(1.16-11.63)	0.027
	LA: no VS yes	20/40.4				7/405		
	Low Middle	32/184 85/341	reference 1.47(0.89-2.45)		- 0.136	7/125 23/309	reference	- 0.723
	High		1.65(0.92-2.95)		0.094	16/172	2.03(0.70-5.89)	0.191
	CMBs: no VS yes Low	55/184	reference	1		23/125	reference	
	Middle		1.01(0.66-1.54)	₽↓↓	- 0.970	57/309	0.86(0.49-1.54)	- 0.617
	High		1.05(0.64-1.75)		0.836		1.30(0.70-2.38)	0.406
	WMH: no VS yes Low	52/184	reference	•	-	20/125	reference	-
	Middle	112/341	1.10(0.70-1.72)	8- 1 8	0.685	63/309	1.19(0.64-2.20)	0.581
	High BVS: no VS vos	58/153	0.96(0.56-1.64)	1	0.871	41/172	1.63(0.85-3.14)	0.143
	PVS: no VS yes Low	121/184	reference	•	-	48/125	reference	-
	Middle	233/341	0.99(0.65-1.50)	₽+-1	0.945	160/309	1.40(0.83-2.33)	0.204
	High	128/153	1.74(0.96-3.15)		0.069	95/172	1.77(1.01-3.11)	0.045

1.5

no Hypertension

Hypertension

medRxiv preprint doi: https://doi.org/10.1101/2024.01.02.24300738; this version posted January 4, 2024. The copyright holder for this SBP variabil

SBP variability prep	rint (vehicitps vas not certified	dhōnyapee	e Akiguristend) ÓR (1959/2011)	perpetuity.	nted m ed/Rixie /a	in as inse	e kodlispelarjo ktresprep	rint in	p value
	cSVD: no VS mild		0	o reuse allowed without	permission.			4	
	Low	62/143	reference	*	-	39/74	reference	•	-
	Middle High	97/229 37/80	1.06(0.67-1.67) 1.09(0.59-1.99)		0.807 0.792	117/174 63/109	1.81(0.99-3.32) 1.39(0.71-2.75)		0.053 0.336
	cSVD: no VS moderate		(,						
	Low	19/100	reference	+	-	28/63	reference	+	-
	Middle High	40/172 14/57	1.32(0.65-2.70) 1.49(0.58-3.83)		0.440 0.411	99/156 52/98	2.10(1.05-4.18) 1.79(0.83-3.85)		0.035 0.138
	cSVD: no VS severe		,						
	Low	14/95	reference	+	-	38/73	reference	+	-
	Middle High	13/145 8/51	0.58(0.22-1.51) 1.02(0.30-3.49)		0.262 0.974	89/146 61/107	1.26(0.61-2.58) 1.70(0.77-3.78)		0.530 0.190
	LA: no VS yes					•			
	Low	8/176	reference	• •	-	37/140	reference	•	-
	Middle High	10/282 10/102	0.80(0.27-2.33) 3.80(1.10-13.19)		0.680	89/362 58/222	0.78(0.47-1.29) 1.12(0.65-1.95)		0.339 0.674
	CMBs: no VS yes	10,102	0.00(1110-10.10)			00,222	1.12(0.00 1.00)		0.011
	Low	37/176	reference		-	50/140			-
	Middle High	46/282 22/102	0.71(0.42-1.18) 0.83(0.43-1.60)		0.185 0.577		2 0.82(0.53-1.29) 1.04(0.64-1.71)		0.389 0.869
	WMH: no VS yes	22/102	0.03(0.43-1.00)		0.577	14/222	1.04(0.04-1.71)		0.009
	Low	25/176	reference	•	-	48/140	reference	•	-
	Middle	45/282	1.22(0.69-2.15)		0.500 0.286		2 0.97(0.61-1.53)		0.882
	High PVS: no VS yes	10/102	0.63(0.27-1.47)		0.286	82/222	1.07(0.64-1.78)		0.790
	Low	76/176	reference	+	-	99/140	reference	+	-
	Middle		1.03(0.66-1.60)		0.911		1.35(0.82-2.24)		0.240
	High	48/102	1.35(0.75-2.45)		0.315	167/222	2 1.62(0.91-2.86)		0.099
	0							0 1 1.0 3	,
DBP variability	Groups	n/N	Adjusted OR(95%CI))	p value	n/N	Adjusted OR(95%CI)		p value
	cSVD: no VS mild Low	55/135	reference	4	_	54/82	reference	4	_
	Low Middle	55/135 94/221	reterence 1.00(0.63-1.59)	→	- 0.993		0.75(0.42-1.34)		- 0.330
	High	47/96	1.24(0.70-2.23)	B-++	0.461	55/95	0.63(0.32-1.22)	I − I − I	0.171
	cSVD: no VS moderate	40/00				20/04			
	Low Middle	18/98 40/167	reference 1.02(0.49-2.11)		- 0.962	36/64 98/168	reference 0.98(0.51-1.89)		- 0.949
	High	15/64	0.98(0.39-2.47)		0.964	45/85	0.71(0.33-1.52)		0.381
	cSVD: no VS severe	0.000		i .		05/00		i	
	Low Middle	9/89 17/144	reference 0.97(0.35-2.73)		- 0.961	35/63 95/165	reference 0.96(0.47-1.95)		- 0.910
	High	9/58	1.03(0.30-3.48)		0.962	58/98	0.99(0.45-2.20)	I	0.985
	LA: no VS yes	0/402		i .		00/150		i	
	Low Middle	6/162 15/278	reference 1.37(0.45-4.13)		- 0.577	33/153 91/373	reference 1.14(0.69-1.88)	p-lamo	- 0.602
	High	7/120	1.68(0.47-6.04)		0.429		1.61(0.93-2.79)		0.002
	CMBs: no VS yes	00							
	Low Middle	30/162 50/278	reference 0.82(0.48-1.40)		- 0.464		reference 1.09(0.70-1.69)		- 0.700
	High	25/120	0.82(0.48-1.40)		0.484		1.32(0.81-2.16)	₽+++-------------	0.700
	WMH: no VS yes			1					
	Low	25/162	reference	* *	-	53/153	reference	+	-
	Middle High	41/278 14/120	0.78(0.44-1.40) 0.52(0.24-1.12)		0.412 0.095		0.95(0.61-1.49) 0.95(0.58-1.57)		0.835 0.849
	PVS: no VS yes		· · · · · · · · · · · · · · · · · · ·	1					2.010
	Low	60/162	reference	+	-		reference	+	-
	Middle High		1.18(0.74-1.87) 1.56(0.87-2.78)		0.492 0.134		1.04(0.64-1.68)		0.886 0.716
		J8/12U	1.00(0.07-2.76)	0 1 1.5 3	5	140/198	0.90(0.52-1.57)	0 1 1.5 3	5
PP variability	Groups	n/N	Adjusted OB(05% CI)		امىد م	n/M	Adjusted OR(95%CI)		n volu-
i i vanabiiity	Groups	n/N	Adjusted OR(95%CI)		p value	n/N	Aujusteu OK(95%CI)		p value
	cSVD: no VS mild	50/122	reference	*		53/92	reference	L	
	Low Middle	50/122 98/234	reterence 0.99(0.62-1.59)	→	- 0.977		0.96(0.55-1.67)		- 0.887
	High	48/96	1.31(0.73-2.34)		0.367	58/86	1.41(0.72-2.77)	•+++++++++++++++++++++++++++++++++++++	0.321
	cSVD: no VS moderate								
	Low Middle	14/86 40/176	reference 1.39(0.64-2.99)	÷	- 0.402	39/78 83/154	reference 0.90(0.48-1.69)		- 0.745
	Middle High	40/176 19/67	1.39(0.64-2.99) 1.68(0.68-4.20)		0.402	83/154 57/85	0.90(0.48-1.69) 1.69(0.80-3.54)		0.745 0.168
	cSVD: no VS severe								
	Low	9/81	reference	+	-	33/72	reference	+	-
	Middle High	17/153 9/57	1.12(0.39-3.20) 1.60(0.47-5.47)		0.836	97/168 58/86	1.31(0.66-2.61) 2.32(1.03-5.22)		0.443
	LA: no VS yes				J 0.101			Ī	2 0.0 IL
	Low	6/145	reference	• • •	-	33/164	reference		-
	Middle High	15/291 7/124	1.60(0.52-4.96) 1.57(0.43-5.76)		0.414	93/359 58/201	1.35(0.82-2.24) 1.64(0.94-2.85)	∎ ∔ ⇒⇒−−−∎	0.242 0.083
	CMBs: no VS yes	11124	1.57(0.43-5.76)		0.499	58/201	1.04(0.34-2.00)		0.083
	Low	29/145	reference	•	-	49/164	reference	•	-
	Middle	51/291	0.77(0.45-1.33)	₽╼┼╼	0.356		1.09(0.70-1.70)		0.691
	High WMH: no VS yes	25/124	0.78(0.41-1.48)		0.442	77/201	1.44(0.88-2.34)		0.145
	Low	18/145	reference	l ∳	-	54/164	reference	4	-
	Middle	42/291	1.17(0.62-2.20)		0.632		0.95(0.61-1.48)		0.812
	High	20/124	1.32(0.62-2.77)	BB	0.471	79/201	0.99(0.60-1.63)		0.970
	PVS: no VS yes Low	55/145	reference		-	111/164	reference		_
	Middle		1.19(0.75-1.89)	→	- 0.465		reference 1.09(0.68-1.75)	▼	- 0.709
	High		1.41(0.80-2.50)		0.239		1.73(0.99-3.04)		0.056
				0 1 1.5 3	5			0 1 15 3	5